Phase 1 Results Presented for Talquetamab, a G Protein–Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, for RRMM

Conference Correspondent —December 16, 2020

GPRC5D, an orphan G protein–coupled receptor, has been identified in bone marrow cells in patients with multiple myeloma (MM). Talquetamab, a first-in-class bispecific antibody (monoclonal antibody that can simultaneously bind to 2 different types of antigen), binds to both GPRC5D on MM cells and CD3 on T-lymphocytes to induce immunologically mediated killing of MM cells. The initial results from an ongoing phase 1 dose-escalation study are presented here.

Patients were eligible for this study if they had measurable MM that either progressed or for which other established therapies were not viable. The primary objectives were to assess the safety of talquetamab and to identify a dose for phase 2 investigation. Secondary objectives were to assess the preliminary efficacy, pharmacokinetics, and pharmacodynamics. Escalating doses of talquetamab (both intravenous [IV] and subcutaneous [SC]) ± step-up doses were assessed.

The median age was 64 years, and 30% of patients were aged ≥70 years. Patients received IV talquetamab (0.5-180 μg/kg; n = 102) or SC talquetamab (5-800 μg/kg; n = 55). Twenty-two percent of patients had ISS stage 3 disease upon entering the study. Patients had received a median of 6 prior therapies. The majority of patients in the trial were refractory to prior therapies; 87% were refractory to the last line of therapy received and 82% were triple-class refractory. Twenty-seven percent of patients (n = 17) had received B-cell maturation antigen–directed therapy.

Anemia, cytokine release syndrome (CRS), neutropenia, and lymphopenia were the most frequent all-grade adverse events (AEs), occurring in 48%, 54%, 47%, and 40% of patients, respectively. The most common grade 3/4 AEs were lymphopenia, anemia, and neutropenia, occurring in 36%, 27%, and 31% of patients, respectively. Most CRS AEs were grade 1/2, with the exception of 5 patients in the IV group (grade 3). CRS generally occurred in the first cycle and appeared within 1 to 2 days of dosing. Six percent of patients (n = 9) experienced treatment-related neurotoxicity. Thirty-eight percent of patients experienced infections (8%), which were grade 3/4. Infusion-related reactions and injection-site reactions were experienced by <20% of patients and were grade 1/2. Dose-limiting toxicities were observed in 3 patients: clinically asymptomatic grade 4 increased lipase in the setting of a pancreatic plasmacytoma with 7.5 μg/kg IV talquetamab, and grade 3 maculopapular rash with 135 μg/kg SC talquetamab (n = 2). The maximum tolerated dose for talquetamab has not been identified.

Weekly IV dosing is supported by the half-life of talquetamab. Increases in T-cell activation and plasma cytokine levels were similar with IV and SC dosing. Step-up dosing was effective at modulating cytokine production while maintaining T-cell activation.

The overall response rate (ORR) was 67% (12/18) for talquetamab IV 20 μg/kg to 180 μg/kg. The ORR was 66% (21/32) for talquetamab SC 135 μg/kg to 405 μg/kg. Responses began at doses as low as 1.0 μg/kg and were rapid (median, 1 month) and durable.

Results from this phase 1 first-in-human study of talquetamab showed encouraging clinical activity with manageable toxicity in heavily pretreated patients with relapsed/refractory multiple myeloma (RRMM). The study is ongoing to identify a dose for the phase 2 investigation.


Reference

Abstract 290. ASH 2020. December 5, 2020. A phase 1, first-in-human study of talquetamab, a G protein-coupled receptor family C group 5 member D (GPRC5D) x CD3 bispecific antibody, in patients with relapsed and/or refractory multiple myeloma (RRMM).

Related Articles
Ixazomib, Lenalidomide, and Dexamethasone in Patients with Newly Diagnosed, Transplant-Eligible Multiple Myeloma
Conference Correspondent
The interim results from a phase 2 trial examining the response to ixazomib, lenalidomide, and dexamethasone induction in newly diagnosed, transplant-eligible patients showed an overall response rate of 93%.
Ciltacabtagene Autoleucel Is a BCMA-Directed Chimeric Antigen Receptor T-Cell Therapy, in RRMM
Conference Correspondent
The preliminary results of the phase 1b/2 CARTITUDE-1 study revealed that early, deep, and durable responses were demonstrated and that a safety profile consistent with prior studies with a single low-dose infusion of ciltacabtagene autoleucel in heavily pretreated patients with RRMM was observed.
ANCHOR: Melflufen plus Dexamethasone and Daratumumab or Bortezomib in RRMM Refractory to an Immunomodulatory Drug and/or a Proteasome Inhibitor
Conference Correspondent
The updated efficacy and safety data from the ANCHOR study of melflufen plus dexamethasone and daratumumab or bortezomib in patients with RRMM demonstrated encouraging efficacy that was well-tolerated.
Last modified: December 16, 2020

Subscribe to the Journal of Oncology Navigation & Survivorship®

To sign up for our print publication or e-newsletter, please enter your contact information below.

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country
  • Please enter your mailing address.

    Address
     
    Address Line 2
    City
     
    State
    Zip Code